Minghan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Minghan Wang has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Christopher Fotsch
Chemistry Research and Development
3 shared publicationsClarence Hale
Departments of Metabolic Disorders
2 shared publicationsDavid J. St. Jean
Chemistry Research and Development
2 shared publicationsKi Won Kim
Departments of Metabolic Disorders
2 shared publicationsRod Cupples
Departments of Metabolic Disorders
2 shared publicationsZhulun Wang
2 shared publications
Latest Publications
- 16 February 2011
- Published by Springer Nature
- No. 203,p. 127-146
Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 in Antidiabetic Therapy
Glucocorticoid action is mediated by glucocorticoid receptor (GR), which upon cortisol binding is activated and regulates the transcriptional expression of target genes and downstream physiological functions. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes the conversion of inactive cortisone to active cortisol. Since cortisol is also produced through biosynthesis in the adrenal glands, the total cortisol level in a given tissue is determined by both the circulating cortisol concentration and the local 11β-HSD1 activity. 11β-HSD1 is expressed in liver, adipose, brain, and placenta. Since it contributes to the local cortisol levels in these tissues, 11β-HSD1 plays a critical role in glucocorticoid action. The metabolic symptoms caused by glucocorticoid excess in Cushing’s syndrome overlap with the characteristics of the metabolic syndrome, suggesting that increased glucocorticoid activity may play a role in the etiology of the metabolic syndrome. Consistent with this notion, elevated adipose expression of 11β-HSD1 induced metabolic syndrome-like phenotypes in mice. Thus, 11β-HSD1 is a proposed therapeutic target to normalize glucocorticoid excess in a tissue-specific manner and mitigate obesity and insulin resistance. Selective inhibitors of 11β-HSD1 are under development for the treatment of type 2 diabetes and other components of the metabolic syndrome.
- 16 February 2011
- Published by Springer Nature
- No. 203,p. 127-146
Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 in Antidiabetic Therapy
Glucocorticoid action is mediated by glucocorticoid receptor (GR), which upon cortisol binding is activated and regulates the transcriptional expression of target genes and downstream physiological functions. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes the conversion of inactive cortisone to active cortisol. Since cortisol is also produced through biosynthesis in the adrenal glands, the total cortisol level in a given tissue is determined by both the circulating cortisol concentration and the local 11β-HSD1 activity. 11β-HSD1 is expressed in liver, adipose, brain, and placenta. Since it contributes to the local cortisol levels in these tissues, 11β-HSD1 plays a critical role in glucocorticoid action. The metabolic symptoms caused by glucocorticoid excess in Cushing’s syndrome overlap with the characteristics of the metabolic syndrome, suggesting that increased glucocorticoid activity may play a role in the etiology of the metabolic syndrome. Consistent with this notion, elevated adipose expression of 11β-HSD1 induced metabolic syndrome-like phenotypes in mice. Thus, 11β-HSD1 is a proposed therapeutic target to normalize glucocorticoid excess in a tissue-specific manner and mitigate obesity and insulin resistance. Selective inhibitors of 11β-HSD1 are under development for the treatment of type 2 diabetes and other components of the metabolic syndrome.
- 13 May 2010
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (11) , 4481-4487
Discovery of a Potent, Orally Active 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor for Clinical Study: Identification of (S)-2-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221)
Thiazolones with an exo-norbornylamine at the 2-position and an isopropyl group on the 5-position are potent 11β-HSD1 inhibitors. However, the C-5 center was prone to epimerization in vitro and in vivo, forming a less potent diastereomer. A methyl group was added to the C-5 position to eliminate epimerization, leading to the discovery of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221). This compound decreased fed blood glucose and insulin levels and reduced body weight in diet-induced obesity mice.
- 13 May 2010
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (11) , 4481-4487
Discovery of a Potent, Orally Active 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor for Clinical Study: Identification of (S)-2-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221)
Thiazolones with an exo-norbornylamine at the 2-position and an isopropyl group on the 5-position are potent 11β-HSD1 inhibitors. However, the C-5 center was prone to epimerization in vitro and in vivo, forming a less potent diastereomer. A methyl group was added to the C-5 position to eliminate epimerization, leading to the discovery of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221). This compound decreased fed blood glucose and insulin levels and reduced body weight in diet-induced obesity mice.
- Open Access
- 28 October 2009
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 74 (6) , 619-624
Resveratrol is Not a Direct Activator of SIRT1 Enzyme Activity
Resveratrol is a plant polyphenol capable of exerting beneficial metabolic effects which are thought to be mediated in large by the activation of the NAD+‐dependent protein deacetylase SIRT1. Although resveratrol has been claimed to be a bona fide SIRT1 activator using a peptide substrate (Fluor de Lys‐SIRT1 peptide substrate), recent reports indicate that this finding might be an experimental artifact and need to be clarified. Here, we show that: (i) the Fluor de Lys‐SIRT1 peptide is an artificial SIRT1 substrate because in the absence of the covalently linked fluorophore the peptide itself is not a substrate of the enzyme, (ii) resveratrol does not activate SIRT1 in vitro in the presence of either a p53‐derived peptide substrate or acetylated PGC‐1α isolated from cells, and (iii) although SIRT1 deacetylates PGC‐1α in both in vitro and cell‐based assays, resveratrol did not activate SIRT1 under these conditions. Based on these observations, we conclude that the pharmacological effects of resveratrol in various models are unlikely to be mediated by a direct enhancement of the catalytic activity of the SIRT1 enzyme. In consequence, our data challenge the overall utility of resveratrol as a pharmacological tool to directly activate SIRT1.
- 28 October 2009
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 74 (6) , 619-624
Open AccessResveratrol is Not a Direct Activator of SIRT1 Enzyme Activity
Resveratrol is a plant polyphenol capable of exerting beneficial metabolic effects which are thought to be mediated in large by the activation of the NAD+‐dependent protein deacetylase SIRT1. Although resveratrol has been claimed to be a bona fide SIRT1 activator using a peptide substrate (Fluor de Lys‐SIRT1 peptide substrate), recent reports indicate that this finding might be an experimental artifact and need to be clarified. Here, we show that: (i) the Fluor de Lys‐SIRT1 peptide is an artificial SIRT1 substrate because in the absence of the covalently linked fluorophore the peptide itself is not a substrate of the enzyme, (ii) resveratrol does not activate SIRT1 in vitro in the presence of either a p53‐derived peptide substrate or acetylated PGC‐1α isolated from cells, and (iii) although SIRT1 deacetylates PGC‐1α in both in vitro and cell‐based assays, resveratrol did not activate SIRT1 under these conditions. Based on these observations, we conclude that the pharmacological effects of resveratrol in various models are unlikely to be mediated by a direct enhancement of the catalytic activity of the SIRT1 enzyme. In consequence, our data challenge the overall utility of resveratrol as a pharmacological tool to directly activate SIRT1.
- 1 May 2009
- Published by Bentham Science Publishers Ltd. in Current Chemical Biology
- Vol. 3 (2) , 159-170
Structure and Inhibitor Binding Mechanisms of 11β -Hydroxysteroid Dehydrogenase Type 1
11β-Hydroxysteroid dehydrogenase (11β-HSD1) is involved in glucocorticoid activation in a tissue-specific manner. In tissues and intact cells, it functions primarily as a reductase by converting inactive cortisone to cortisol. Since glucocorticoid action is implicated in the development of the metabolic syndrome, inhibition of 11β-HSD1 has been proposed as a therapeutic strategy to treat type 2 diabetes. 11β-HSD1 is a member of the short chain dehydrogenase/reductase (SDR) superfamily with the “Y183SASK187” sequence and Ser170 at the active site that matches the catalytic domain signature motif of “YXXXK” in SDRs. The recent success in the determination of various 11β-HSD1 3-dimentional structures has facilitated a higher level understanding of the interactions among the enzyme, the cofactor and the substrate as well as substrate site inhibitors. In particular, the structural analysis of 11β-HSD1 in complex with a non-selective inhibitor carbenoxolone (CBX) has advanced our knowledge of inhibitor-enzyme interactions. In addition to the catalytic triad, residues close to the steroid binding site and surrounding areas have been identified as important in stabilizing the substrate. These findings have accelerated medicinal chemistry efforts to discover selective 11β-HSD1 inhibitors in the pharmaceutical industry. A large number of chemical classes have been identified as potent and selective 11β-HSD1 inhibitors. Some common features in enzyme-inhibitor interactions were observed with structurally distinct compounds. Chemical class-specific interactions were discovered as well, which explain the structural diversity of selective 11β-HSD1 inhibitors. In this article, we review the structural characteristics of 11β-HSD1 enzymes in several species. By comparing active sites, substrate binding and subunit interactions, we have identified structural features and residues in the active site important for inhibitor binding. Further, through analysis of the major interactions between the active site residues and inhibitors of different chemical classes, we have determined compound class-specific structural requirements for optimal enzyme- inhibitor interaction.
- 1 May 2009
- Published by Bentham Science Publishers Ltd. in Current Chemical Biology
- Vol. 3 (2) , 159-170
Structure and Inhibitor Binding Mechanisms of 11β -Hydroxysteroid Dehydrogenase Type 1
11β-Hydroxysteroid dehydrogenase (11β-HSD1) is involved in glucocorticoid activation in a tissue-specific manner. In tissues and intact cells, it functions primarily as a reductase by converting inactive cortisone to cortisol. Since glucocorticoid action is implicated in the development of the metabolic syndrome, inhibition of 11β-HSD1 has been proposed as a therapeutic strategy to treat type 2 diabetes. 11β-HSD1 is a member of the short chain dehydrogenase/reductase (SDR) superfamily with the “Y183SASK187” sequence and Ser170 at the active site that matches the catalytic domain signature motif of “YXXXK” in SDRs. The recent success in the determination of various 11β-HSD1 3-dimentional structures has facilitated a higher level understanding of the interactions among the enzyme, the cofactor and the substrate as well as substrate site inhibitors. In particular, the structural analysis of 11β-HSD1 in complex with a non-selective inhibitor carbenoxolone (CBX) has advanced our knowledge of inhibitor-enzyme interactions. In addition to the catalytic triad, residues close to the steroid binding site and surrounding areas have been identified as important in stabilizing the substrate. These findings have accelerated medicinal chemistry efforts to discover selective 11β-HSD1 inhibitors in the pharmaceutical industry. A large number of chemical classes have been identified as potent and selective 11β-HSD1 inhibitors. Some common features in enzyme-inhibitor interactions were observed with structurally distinct compounds. Chemical class-specific interactions were discovered as well, which explain the structural diversity of selective 11β-HSD1 inhibitors. In this article, we review the structural characteristics of 11β-HSD1 enzymes in several species. By comparing active sites, substrate binding and subunit interactions, we have identified structural features and residues in the active site important for inhibitor binding. Further, through analysis of the major interactions between the active site residues and inhibitors of different chemical classes, we have determined compound class-specific structural requirements for optimal enzyme- inhibitor interaction.
- 1 November 2008
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 8 (17) , 1508-1523
Inhibitors of 11β-HSD1: A Potential Treatment for the Metabolic Syndrome
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme that converts cortisone to cortisol. A growing body of evidence suggests that selective inhibition of 11β-HSD1 could potentially treat the metabolic syndrome. This review provides an overview of compounds reported to have in vivo inhibitory activity against this enzyme. A major focus of this review is Amgens 11β-HSD1 program which includes a variety of in vivo data for a lead compound from our thiazolone class of inhibitors. Finally, an update on the current known clinical data is discussed.
- 1 November 2008
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 8 (17) , 1508-1523
Inhibitors of 11β-HSD1: A Potential Treatment for the Metabolic Syndrome
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme that converts cortisone to cortisol. A growing body of evidence suggests that selective inhibition of 11β-HSD1 could potentially treat the metabolic syndrome. This review provides an overview of compounds reported to have in vivo inhibitory activity against this enzyme. A major focus of this review is Amgens 11β-HSD1 program which includes a variety of in vivo data for a lead compound from our thiazolone class of inhibitors. Finally, an update on the current known clinical data is discussed.
- 7 December 2007
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 71 (1) , 36-44
Structural Characterization and Pharmacodynamic Effects of an Orally Active 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor
11Beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid action and inhibition of this enzyme is a viable therapeutic strategy for the treatment of type 2 diabetes and the metabolic syndrome. Here, we report a potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor with a binding mode elucidated from the co-crystal structure with the human 11beta-hydroxysteroid dehydrogenase type 1. The inhibitor is bound to the steroid-binding pocket making contacts with the catalytic center and the solvent channel. The inhibitor binding is facilitated by two direct hydrogen bond interactions involving Tyrosine183 of the catalytic motif Tyr-X-X-X-Lys and Alanine172. In addition, the inhibitor makes many hydrophobic interactions with both the enzyme and the co-factor nicotinamide adenine dinucleotide phosphate (reduced). In lean C57BL/6 mice, the compound inhibited both the in vivo and ex vivo 11beta-hydroxysteroid dehydrogenase type 1 activities in a dose-dependent manner. The inhibitory effects correlate with the plasma compound concentrations, suggesting that there is a clear pharmacokinetic and pharmacodynamic relationship. Moreover, at the same doses used in the pharmacokinetic/pharmacodynamic studies, the inhibitor did not cause the activation of the hypothalamic-pituitary-adrenal axis in an acute mouse model, suggesting that this compound exhibits biological effects with minimal risk of activating the hypothalamic-pituitary-adrenal axis.
- 7 December 2007
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 71 (1) , 36-44
Structural Characterization and Pharmacodynamic Effects of an Orally Active 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor
11Beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid action and inhibition of this enzyme is a viable therapeutic strategy for the treatment of type 2 diabetes and the metabolic syndrome. Here, we report a potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor with a binding mode elucidated from the co-crystal structure with the human 11beta-hydroxysteroid dehydrogenase type 1. The inhibitor is bound to the steroid-binding pocket making contacts with the catalytic center and the solvent channel. The inhibitor binding is facilitated by two direct hydrogen bond interactions involving Tyrosine183 of the catalytic motif Tyr-X-X-X-Lys and Alanine172. In addition, the inhibitor makes many hydrophobic interactions with both the enzyme and the co-factor nicotinamide adenine dinucleotide phosphate (reduced). In lean C57BL/6 mice, the compound inhibited both the in vivo and ex vivo 11beta-hydroxysteroid dehydrogenase type 1 activities in a dose-dependent manner. The inhibitory effects correlate with the plasma compound concentrations, suggesting that there is a clear pharmacokinetic and pharmacodynamic relationship. Moreover, at the same doses used in the pharmacokinetic/pharmacodynamic studies, the inhibitor did not cause the activation of the hypothalamic-pituitary-adrenal axis in an acute mouse model, suggesting that this compound exhibits biological effects with minimal risk of activating the hypothalamic-pituitary-adrenal axis.
- 1 October 2006
- Published by Elsevier in Chemistry & Biology
- Vol. 13 (10) , 1019-1027
Small-Molecule Compounds that Modulate Lipolysis in Adipose Tissue: Targeting Strategies and Molecular Classes
- 1 October 2006
- Published by Elsevier in Chemistry & Biology
- Vol. 13 (10) , 1019-1027
Small-Molecule Compounds that Modulate Lipolysis in Adipose Tissue: Targeting Strategies and Molecular Classes
- 1 July 2006
- Published by Wiley in Drug Development Research
- Vol. 67 (7) , 567-569
Tissue‐specific glucocorticoid excess in the metabolic syndrome: 11β‐HSD1 as a therapeutic target
- 1 July 2006
- Published by Wiley in Drug Development Research
- Vol. 67 (7) , 567-569
Tissue‐specific glucocorticoid excess in the metabolic syndrome: 11β‐HSD1 as a therapeutic target
- 1 April 2006
- Vol. 7 (4) , 319-23
Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
Metabolic syndrome is a group of metabolic abnormalities associated with increased cardiovascular and mortality risks. Glucocorticoid excess has been linked to the development of metabolic syndrome. Intracellular glucocorticoid levels are regulated by 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1), a key enzyme that converts inert cortisone to active cortisol. To counter the unfavorable metabolic effects of glucocorticoids in certain tissues, 11beta-HSD-1 inhibitors are being investigated for their potential in the treatment of insulin resistance and other aspects of metabolic syndrome. Several different classes of 11beta-HSD-1 inhibitors are currently under investigation by multiple pharmaceutical companies, highlighting the encouraging progress made in this field.
- 1 April 2006
- Vol. 7 (4) , 319-23
Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
Metabolic syndrome is a group of metabolic abnormalities associated with increased cardiovascular and mortality risks. Glucocorticoid excess has been linked to the development of metabolic syndrome. Intracellular glucocorticoid levels are regulated by 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1), a key enzyme that converts inert cortisone to active cortisol. To counter the unfavorable metabolic effects of glucocorticoids in certain tissues, 11beta-HSD-1 inhibitors are being investigated for their potential in the treatment of insulin resistance and other aspects of metabolic syndrome. Several different classes of 11beta-HSD-1 inhibitors are currently under investigation by multiple pharmaceutical companies, highlighting the encouraging progress made in this field.
- Open Access
- 2 February 2005
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 2 (1) , 3
The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome
Glucocorticoids are stress hormones that modulate a large number of physiological actions involved in metabolic, inflammatory, cardiovascular and behavioral processes. The molecular mechanisms and the physiological effects of glucocorticoids have been extensively studied. However, the involvement of glucocorticoid action in the etiology of the Metabolic Syndrome has not been well appreciated. Recently, accumulating clinical evidence and animal genetics studies have attracted growing interest in the role of glucocorticoid action in obesity and insulin resistance. This review will discuss the metabolic effects in the context of glucocorticoid metabolism and establish the association of glucocorticoid action with the features of the Metabolic Syndrome, especially obesity and insulin resistance. Special discussions will be focused on corticosteroid-binding globulin and 11β-hydroxysteroid dehydrogenase type 1, two proteins that mediate glucocorticoid action and have been implicated in the Metabolic Syndrome. Due to the complexities of the glucocorticoid biology and the Metabolic Syndrome and limited space, this review is only intended to provide a general link between the two areas with broad rather than in-depth discussions of clinical, pharmacological and genetic findings.
- 2 February 2005
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 2 (1) , 3
Open AccessThe role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome
Glucocorticoids are stress hormones that modulate a large number of physiological actions involved in metabolic, inflammatory, cardiovascular and behavioral processes. The molecular mechanisms and the physiological effects of glucocorticoids have been extensively studied. However, the involvement of glucocorticoid action in the etiology of the Metabolic Syndrome has not been well appreciated. Recently, accumulating clinical evidence and animal genetics studies have attracted growing interest in the role of glucocorticoid action in obesity and insulin resistance. This review will discuss the metabolic effects in the context of glucocorticoid metabolism and establish the association of glucocorticoid action with the features of the Metabolic Syndrome, especially obesity and insulin resistance. Special discussions will be focused on corticosteroid-binding globulin and 11β-hydroxysteroid dehydrogenase type 1, two proteins that mediate glucocorticoid action and have been implicated in the Metabolic Syndrome. Due to the complexities of the glucocorticoid biology and the Metabolic Syndrome and limited space, this review is only intended to provide a general link between the two areas with broad rather than in-depth discussions of clinical, pharmacological and genetic findings.